Form D · Biotechnology
Regenimo Biosciences, Inc.
Houston, TX · CIK 0002096367
Offering snapshot reported Nov 25, 2025 · SEC filing
- Reported sold
- $2M Offering amount: $2M
- Investors reported
- 6 Form D · investor count
- Minimum accepted
- $50K Reported outside-investor minimum
- First sale
- Nov 10, 2025 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Nov 25, 2025 | Initial | $2,000,000 | No comparison | 6 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-564953
Source: Form D, filed Nov 25, 2025. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Lynda Chin | Director |
| Raju Kucherlapati | Director |
| Sharon Shacham | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
3262 Westheimer Rd. #762
Houston, TX, 77098
Houston, TX, 77098